159 related articles for article (PubMed ID: 22753741)
1. Efficacy of combination chemotherapy using oral fluoropyrimidine S-1 with oxaliplatin (SOX) against colorectal cancer in vivo.
Nukatsuka M; Saito H; Sakamoto K; Nakagawa F; Uchida J; Kobunai T; Shiraishi K; Takechi T
Anticancer Res; 2012 Jul; 32(7):2807-12. PubMed ID: 22753741
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of capecitabine efficacy by oxaliplatin in human colorectal and gastric cancer xenografts.
Sawada N; Kondoh K; Mori K
Oncol Rep; 2007 Oct; 18(4):775-8. PubMed ID: 17786335
[TBL] [Abstract][Full Text] [Related]
3. Oral fluoropyrimidine treatment of colorectal cancer.
Eng C; Kindler HL; Schilsky RL
Clin Colorectal Cancer; 2001 Aug; 1(2):95-103. PubMed ID: 12445367
[TBL] [Abstract][Full Text] [Related]
4. A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer.
Kim GM; Jeung HC; Rha SY; Kim HS; Jung I; Nam BH; Lee KH; Chung HC
Eur J Cancer; 2012 Mar; 48(4):518-26. PubMed ID: 22243774
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of bevacizumab in combination with capecitabine and oxaliplatin in human colorectal cancer xenograft models.
Yanagisawa M; Fujimoto-Ouchi K; Yorozu K; Yamashita Y; Mori K
Oncol Rep; 2009 Aug; 22(2):241-7. PubMed ID: 19578762
[TBL] [Abstract][Full Text] [Related]
6. S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial.
Kim ST; Hong YS; Lim HY; Lee J; Kim TW; Kim KP; Kim SY; Baek JY; Kim JH; Lee KW; Chung IJ; Cho SH; Lee KH; Shin SJ; Kang HJ; Shin DB; Lee JW; Jo SJ; Park YS
BMC Cancer; 2014 Nov; 14():883. PubMed ID: 25424120
[TBL] [Abstract][Full Text] [Related]
7. Capecitabine plus oxaliplatin for the treatment of colorectal cancer.
Carrato A; Gallego-Plazas J; Guillén-Ponce C
Expert Rev Anticancer Ther; 2008 Feb; 8(2):161-74. PubMed ID: 18279056
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models.
Ouchi KF; Yanagisawa M; Sekiguchi F; Tanaka Y
Cancer Chemother Pharmacol; 2006 May; 57(5):693-702. PubMed ID: 16362295
[TBL] [Abstract][Full Text] [Related]
9. Feasibility study of oxaliplatin with oral S-1 or capecitabine as first-line therapy for patients with metastases from colorectal cancer.
Watanabe K; Kawahara H; Enomoto H; Toyama Y; Akiba T; Yanaga K
Anticancer Res; 2013 Sep; 33(9):4029-32. PubMed ID: 24023346
[TBL] [Abstract][Full Text] [Related]
10. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer.
Cassidy J; Tabernero J; Twelves C; Brunet R; Butts C; Conroy T; Debraud F; Figer A; Grossmann J; Sawada N; Schöffski P; Sobrero A; Van Cutsem E; Díaz-Rubio E
J Clin Oncol; 2004 Jun; 22(11):2084-91. PubMed ID: 15169795
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats.
Shirasaka T; Nakano K; Takechi T; Satake H; Uchida J; Fujioka A; Saito H; Okabe H; Oyama K; Takeda S; Unemi N; Fukushima M
Cancer Res; 1996 Jun; 56(11):2602-6. PubMed ID: 8653704
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts.
Nukatsuka M; Nakagawa F; Takechi T
Anticancer Res; 2015 Sep; 35(9):4605-15. PubMed ID: 26254349
[TBL] [Abstract][Full Text] [Related]
13. Combined therapy with a thymidylate synthase-inhibiting vector and S-1 has effective antitumor activity against 5-FU-resistant tumors.
Kadota K; Huang CL; Liu D; Yokomise H; Haba R; Wada H
Int J Oncol; 2011 Feb; 38(2):355-63. PubMed ID: 21174056
[TBL] [Abstract][Full Text] [Related]
14. The SOFT trial: a Phase III study of the dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 and oxaliplatin (SOX) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer.
Nakamura M; Yamada Y; Muro K; Takahashi K; Baba H; Sasaki Y; Komatsu Y; Satoh T; Mishima H; Watanabe M; Sakata Y; Morita S; Shimada Y; Sugihara K
Future Oncol; 2015; 11(10):1471-8. PubMed ID: 25963425
[TBL] [Abstract][Full Text] [Related]
15. S-1, an oral fluoropyrimidine, enhances radiation response of DLD-1/FU human colon cancer xenografts resistant to 5-FU.
Nakata E; Fukushima M; Takai Y; Nemoto K; Ogawa Y; Nomiya T; Nakamura Y; Milas L; Yamada S
Oncol Rep; 2006 Sep; 16(3):465-71. PubMed ID: 16865244
[TBL] [Abstract][Full Text] [Related]
16. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108.
Comella P; Natale D; Farris A; Gambardella A; Maiorino L; Massidda B; Casaretti R; Tafuto S; Lorusso V; Leo S; Cannone M
Cancer; 2005 Jul; 104(2):282-9. PubMed ID: 15948167
[TBL] [Abstract][Full Text] [Related]
17. [Benefits of TS-1 plus leucovorin combination therapy for colorectal cancer: evaluation of therapeutic effect of TS-1 and leucovorin combination therapy using rodent model fed a low folate diet].
Tsujimoto H; Tsukioka S; Koizumi K; Nakagawa F; Uchida J; Sugimoto Y; Oka T; Fukushima M; Watanabe T
Gan To Kagaku Ryoho; 2007 Mar; 34(3):413-8. PubMed ID: 17353633
[TBL] [Abstract][Full Text] [Related]
18. Irinotecan overcomes the resistance to 5-fluorouracil in human colon cancer xenografts by down-regulation of intratumoral thymidylate synthase.
Fukushima M; Sakamoto K; Ohshimo H; Nakagawa F; Taguchi T
Oncol Rep; 2010 Oct; 24(4):835-42. PubMed ID: 20811661
[TBL] [Abstract][Full Text] [Related]
19. Patients with locally advanced and metastatic colorectal cancer treated with capecitabine versus 5-fluorouracil as monotherapy or combination therapy with oxaliplatin: a cost comparison.
Chu E; Schulman KL; McKenna EF; Cartwright T
Clin Colorectal Cancer; 2010 Oct; 9(4):229-37. PubMed ID: 20920995
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of a combination of trastuzumab (Herceptin) and oral fluoropyrimidine S-1 on human epidermal growth factor receptor 2-overexpressing pancreatic cancer.
Saeki H; Yanoma S; Takemiya S; Sugimasa Y; Akaike M; Yukawa N; Rino Y; Imada T
Oncol Rep; 2007 Aug; 18(2):433-9. PubMed ID: 17611667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]